TRAVERE THERAPEUTICS INC. - COMMON STOCK

19.73

14-March-25 16:45:00

15 minutes delayed

Stocks

+0.60

+3.14%

Today's range

18.86 - 19.87

ISIN

N/A

Source

NASDAQ

Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors

14 Sep 2021 16:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Sep 2021 17:00:00 By Nasdaq GlobeNewswire
Travere Therapeutics Announces Successful Outcome from Type A Meeting with U.S. FDA for Sparsentan in Focal Segmental Glomerulosclerosis

07 Sep 2021 08:00:02 By Nasdaq GlobeNewswire
Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

16 Aug 2021 07:00:02 By Nasdaq GlobeNewswire
Travere Therapeutics Reports Second Quarter 2021 Financial Results

29 Jul 2021 16:01:00 By Nasdaq GlobeNewswire
Travere Therapeutics to Report Second Quarter 2021 Financial Results

22 Jul 2021 16:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Jul 2021 16:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics Announces Presentation of Abstracts at ERA-EDTA Congress 2021

04 Jun 2021 08:00:00 By Nasdaq GlobeNewswire
Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

02 Jun 2021 08:00:01 By Nasdaq GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences

27 May 2021 16:30:00 By Nasdaq GlobeNewswire

<<
<
4
5
6
7
8
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.